Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors

A third of patients with non-small cell lung cancer (NSCLC) present with un-resectable stage III locally advanced disease and are currently treated by chemo-radiotherapy but the median survival is only about 21 months. Using an orthotopic xenograft model of lung carcinoma, we have investigated the c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hillman, Gilda G., Lonardo, Fulvio, Hoogstra, David J., Rakowski, Joseph, Yunker, Christopher K., Joiner, Michael C., Dyson, Gregory, Gadgeel, Shirish, Singh-Gupta, Vinita
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4145357/
https://ncbi.nlm.nih.gov/pubmed/24862536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2014.04.002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars